BACKGROUND: Taxanes cause hypersensitivity reactions, averted by premedication with H1 blockers and high glucocorticoid (GC) doses. Prolonged weekly taxane administration may lead to GC toxicity. PURPOSE: To determine whether patients not hypersensitive to initial paclitaxel (PTX) infusion after high-dose GC premedication will tolerate subsequent, prolonged PTX treatment without GC prophylaxis. PATIENTS AND METHODS: In 115/122 breast cancer patients not hypersensitive to initial PTX treatment, 20 mg dexamethasone (DXM) doses were tapered by 2.0 mg/week, reaching 0 in those receiving 9 or more courses. After 4 PTX courses, diphenhydramine was administered orally, rather than intravenously. RESULTS: PTX was administered 143 times after 2.0-5.0 mg of DXM and 357 times without DXM. A total of 46 patients received 1-40 PTX courses without DXM. None of these 115 patients experienced hypersensitivity reactions. CONCLUSION: Patients unreactive to their first PTX infusions, after high-dose and tapering GC premedication, may not require GC prophylaxis for subsequent PTX therapy. Copyright 2005 S. Karger AG, Basel
BACKGROUND:Taxanes cause hypersensitivity reactions, averted by premedication with H1 blockers and high glucocorticoid (GC) doses. Prolonged weekly taxane administration may lead to GC toxicity. PURPOSE: To determine whether patients not hypersensitive to initial paclitaxel (PTX) infusion after high-dose GC premedication will tolerate subsequent, prolonged PTX treatment without GC prophylaxis. PATIENTS AND METHODS: In 115/122 breast cancerpatients not hypersensitive to initial PTX treatment, 20 mg dexamethasone (DXM) doses were tapered by 2.0 mg/week, reaching 0 in those receiving 9 or more courses. After 4 PTX courses, diphenhydramine was administered orally, rather than intravenously. RESULTS:PTX was administered 143 times after 2.0-5.0 mg of DXM and 357 times without DXM. A total of 46 patients received 1-40 PTX courses without DXM. None of these 115 patients experienced hypersensitivity reactions. CONCLUSION:Patients unreactive to their first PTX infusions, after high-dose and tapering GC premedication, may not require GC prophylaxis for subsequent PTX therapy. Copyright 2005 S. Karger AG, Basel
Authors: Ka-Eun Yoo; Rae Young Kang; Ju-Yeun Lee; Yu Jeung Lee; Sung Yun Suh; Kwi Suk Kim; Hyang Sook Kim; Se-Hoon Lee; Byung Koo Lee Journal: Support Care Cancer Date: 2014-12-13 Impact factor: 3.603
Authors: Michael J Berger; Craig Vargo; Mary Vincent; Katy Shaver; Gary Phillips; Rachel Layman; Erin Macrae; Ewa Mrozek; Bhuvaneswari Ramaswamy; Robert Wesolowski; Charles L Shapiro; Maryam B Lustberg Journal: Support Care Cancer Date: 2014-12-18 Impact factor: 3.603
Authors: Samuel Dubinsky; Deep Patel; Xiang Wang; Amirrtha Srikanthan; Terry L Ng; Corey Tsang Journal: Support Care Cancer Date: 2022-02-12 Impact factor: 3.603
Authors: Michael J Berger; Leslie J Dunlea; Amy E Rettig; Maryam B Lustberg; Gary S Phillips; Charles L Shapiro Journal: Support Care Cancer Date: 2011-11-17 Impact factor: 3.603